Results
We found that the inflamed, chemokine-rich vaccination site potently attracted and sequestered anti-CTLA-4 activated effector T cells with antigen-specificities unrelated to the gp100/IFA vaccine. Some of the tumorspecific T cells induced by anti-CTLA-4 therapy recognized the melanocyte differentiation antigen, TRP-2, allowing us to quantify their number and localization at the tumor and vaccination site. Anti-CTLA-4 monotherapy significantly increased the absolute number of TRP-2-specific effector T cells at the tumor site at the time of tumor suppression. Remarkably, gp100/IFA vaccination induced sequestration at the vaccination site not only of gp100-specific T cells, but also of TRP-2-specific T cells, dramatically reducing their numbers at the tumor site. In addition, gp100/IFA vaccination slightly reduced therapeutic efficacy of anti-CTLA-4 therapy, replicating the reported clinical observation. In contrast, a non-persistent vaccine formulation, Vesicular Stomatitis Virus encoding gp100 (VSV.gp100) synergized with anti-CTLA-4 to enhance anti-tumor activity. Finally, vaccination also synergized with anti-PD-1 therapy, and with anti-CTLA-4 + anti-PD-1 combination therapy. Immunohistochemistry analysis showed co-localization of CD8+ T cells mainly in ICAM-1 expressing sections of the tumor stroma. ICAM-1 deficiency in host mice resulted in significant abrogation of the anti-tumor activity. Similarly, mice treated with anti-CXCR3 mAb versus control (IgG mAb) showed significant decrease in survival, which correlated with decrease in intra-tumoral CD8+ T cell count at the time of the treatment.
Conclusion
In conclusion, a non-persistent vaccine formulation can reverse the undesirable effect of the persistent vaccine formulation and synergizes with anti-CTLA-4 and/or anti-PD-1 therapies, resulting in significantly improved anti-tumor activity.
